Anavex Life Sciences Corp. announced the appointment of David Goldberger, RPh, MLS as Senior Vice President Regulatory Affairs. Mr. Goldberger brings over 40 years of pharmacy practice and pharmaceutical industry experience and has most recently been with Otsuka Pharmaceuticals Research and Development (Otsuka) as Vice President Global Regulatory Affairs, U.S. and Europe.

Mr. Goldberger will succeed retiring Senior Vice President Regulatory Affairs, Emmanuel O Fadiran, RPh, MS, PhD. Before joining Anavex Mr. Goldberger has most recently been with Otsuka where he led the Regulatory Affairs efforts to gain approval for multiple CNS products, including ABILIFY MAINTENA(R), REXULTI(R), new indications for ABILIFY(R) as well other product and therapeutic area approvals. Prior to Otsuka he held senior level positions in Global Regulatory Affairs for Johnson and Johnson (J&J) Pharmaceutical Research and Development in Global Regulatory Affairs.

Throughout his career he has covered the full range of investigational products development and marketed products across multiple therapeutic areas including psychiatry and neurology. Mr. Goldberger has extensive experience in working with the U.S. FDA, EMA, Health Canada, and other global health authorities. In addition, he led CMC Regulatory Affairs, Labeling, Regulatory Operations/Technology and Medical Writing areas.

Mr. Goldberger holds bachelor's and master's degrees from Rutgers University.